Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 1
2015 2
2016 3
2018 1
2019 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Results by year
Filters applied: . Clear all
Page 1
The safety of new drug treatments for idiopathic pulmonary fibrosis.
Fletcher S, Jones MG, Spinks K, Sgalla G, Marshall BG, Limbrey R, Richeldi L. Fletcher S, et al. Among authors: spinks k. Expert Opin Drug Saf. 2016 Nov;15(11):1483-1489. doi: 10.1080/14740338.2016.1218470. Epub 2016 Aug 17. Expert Opin Drug Saf. 2016. PMID: 27532218 Review.
Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice.
Fletcher SV, Jones MG, Renzoni EA, Parfrey H, Hoyles RK, Spinks K, Kokosi M, Kwok A, Warburton C, Titmuss V, Thillai M, Simler N, Maher TM, Brereton CJ, Chua F, Wells AU, Richeldi L, Spencer LG. Fletcher SV, et al. Among authors: spinks k. ERJ Open Res. 2018 Oct 19;4(4):00049-2018. doi: 10.1183/23120541.00049-2018. eCollection 2018 Oct. ERJ Open Res. 2018. PMID: 30364342 Free PMC article.